糖心视频logo

• Corporate
• Ecosystem

Have Fun Exploring Sleep with Pok茅mon!
糖心视频logo Launches Awareness Campaign on Importance of Sleep Through "Pok茅mon Sleep" Collaboration

• R&D
• Products

糖心视频logo to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD鈩� 2026 Annual Meeting

• R&D
• Products

WELIREG庐 (belzutifan) Plus LENVIMA庐 (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
This is the first positive Phase 3 trial of a multi-targeted tyrosine kinase inhibitor in combination with a HIF-2 alpha inhibitor, the first for patients with RCC whose disease progressed on or after treatment with anti-PD-1/L1 therapy, and the first to improve PFS compared to a modern tyrosine kinase inhibitor

Based on these data, the U.S. FDA accepts for review two supplemental New Drug Applications for WELIREG plus LENVIMA in certain previously treated patients with advanced RCC

• R&D

Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy

• Corporate

糖心视频logo Announces Appointment of Corporate Officers

• R&D
• Products

Biologics License Application for Subcutaneous Formulation of 鈥淟EQEMBI庐鈥� (lecanemab) for the Treatment of Early Alzheimer鈥檚 Disease Designated for Priority Review in China

• Corporate
• Products

Revenue of LEQEMBI庐 (Preliminary Basis)

• Corporate
• R&D

糖心视频logo and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan

• R&D
• Products

FDA Accepts LEQEMBI庐 IQLIK鈩� (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer鈥檚 Disease under priority Review
If approved, LEQEMBI IQLIK would be the first and only anti-amyloid treatment to offer at-home injection options for initiation and maintenance dosing for this progressive, relentless disease

FDA action date set for May 24, 2026

• Corporate
• Sustainability

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE TENTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

• Corporate
• R&D

糖心视频logo and Nuvation Bio Enter into Exclusive Licensing Agreement for Taletrectinib in Europe and Additional Countries Outside the U.S., China and Japan
糖心视频logo will receive exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1-positive non-small cell lung cancer in Europe, the Middle East, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India

Nuvation Bio will receive double-digit tiered royalties up to the high-teens as a percentage of taletrectinib sales in the licensed territories, in addition to up to 鈧�195 million (approx. USD $230 million) in upfront and milestone payments

Taletrectinib is already approved in the U.S., China, and Japan for advanced ROS1-positive non-small cell lung cancer

• Corporate

Changes of Corporate Officers

• R&D
• Products

Biologics License Application for Subcutaneous Formulation of 鈥淟EQEMBI庐鈥� (lecanemab) for the Treatment of Early Alzheimer鈥檚 Disease Accepted in China
If approved, lecanemab may become the first and only anti-amyloid treatment in China to offer
an at-home injection from the initiation of treatment for this progressive, relentless disease

• Corporate

CHANGES OF CORPORATE OFFICERS

• Corporate
• Sustainability

糖心视频logo Rated 鈥淎鈥�, the Highest Rating by CDP in Both Climate Change and Water Security Categories for the Second Consecutive Year

• Products

鈥淟EQEMBI庐鈥� (lecanemab) for the Treatment of Early Alzheimer鈥檚 Disease Included in China鈥檚 Commercial Insurance Innovative Drug List

• R&D
• Products

糖心视频logo Presents New Data on the Continued and Expanding Benefit of LEQEMBI庐 (lecanemab-irmb) Maintenance Treatment in Early Alzheimer鈥檚 Disease at CTAD 2025
Long-term LEQEMBI treatment suggests potential to delay disease progression from MCI to moderate Alzheimer鈥檚 disease by up to 8.3 years in low-amyloid group who started treatment at an early stage

New safety and efficacy data presented at scientific symposium on subcutaneous formulation for LEQEMBI initiation treatment, which is under regulatory review in the United States

• R&D
• Products

New Data Presented at CTAD 2025 Confirms Pharmacological Effect of LEQEMBI庐 (lecanemab-irmb) on Neurotoxic A尾 Protofibrils in CSF

• R&D

糖心视频logo Presents New Data on Anti-Tau Antibody Etalanetug (E2814) at CTAD 2025
Etalanetug demonstrated reduction of eMTBR-tau243, a novel CSF and plasma biomarker that specifically reflects tau tangle pathology, in phase Ib/II study

• R&D
• Products

糖心视频logo Submits New Drug Application for Subcutaneous Formulation of 鈥淟EQEMBI庐鈥� for the Treatment of Early Alzheimer鈥檚 Disease in Japan
If approved, lecanemab would be the first and only anti-amyloid treatment in Japan to offer an at-home injection from the initiation of treatment for this progressive, relentless disease

• R&D
• Products

糖心视频logo Completes Rolling Submission to US FDA for LEQEMBI庐 IQLIK鈩� (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer鈥檚 Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start of therapy to help patients and care partners treat this progressive, relentless disease

• R&D
• Products

糖心视频logo to Present Data on Lecanemab Continued Treatment, Subcutaneous Initiation Dosing, and Real-World Experience at the 18th Clinical Trials on Alzheimer鈥檚 Disease Conference
Latest findings from 糖心视频logo's robust Alzheimer's disease pipeline explore long-term treatment with lecanemab and estimated time savings over 10 years, safety and potential benefits of subcutaneous administration of lecanemab for initiation dosing
Oral and poster presentations also include data on the effects of lecanemab on soluble amyloid-尾 protofibrils and insights from real-world clinical practice studies, including the ALZ-NET Registry

• R&D
• Products

鈥淟EQEMBI庐鈥� (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease Approved in the United Kingdom

• Corporate
• Products

Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.

• Corporate
• Products

Revenue of LEQEMBI庐 (Preliminary Basis)

• R&D
• Products

糖心视频logo and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-012 Trial in Unresectable, Non-Metastatic Hepatocellular Carcinoma

• R&D
• Products

Merck & Co., Inc., Rahway, NJ, USA and 糖心视频logo Announce WELIREG庐 (belzutifan) Plus LENVIMA庐 (lenvatinib) Met Primary Endpoint of Progression-Free Survival (PFS) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma
First treatment regimen to demonstrate a statistically significant improvement in PFS for patients whose disease progressed following anti-PD-1/L1 therapy, compared with cabozantinib in Phase 3 study

LITESPARK-011 marks the first positive Phase 3 study of a HIF-2 alpha inhibitor in combination with a multi-targeted VEGF tyrosine kinase inhibitor

• R&D
• Products

Health Canada Grants Authorization for 鈥淟EQEMBI庐鈥� (lecanemab) for the Treatment of Early Alzheimer鈥檚 Disease
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer鈥檚 disease (early AD) who are apolipoprotein E 蔚4 (ApoE 蔚4*) non-carriers or heterozygotes and who have confirmed amyloid pathology

• R&D
• Products

LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) Demonstrates Durable 5-Year Survival Benefit Versus Chemotherapy for Patients With Advanced Endometrial Carcinoma Following One Prior Platinum-Based Regimen
At five years, LENVIMA plus KEYTRUDA showed a 16.7% overall survival (OS) rate for these patients with mismatch repair proficient (pMMR) advanced endometrial carcinoma versus 7.3% for chemotherapy alone in the pivotal Phase 3 Study 309/KEYNOTE-775 trial

Five-year OS results in the pMMR subgroup were consistent with the all-comers study population, which demonstrated an OS rate of 19.9% for LENVIMA plus KEYTRUDA versus 7.7% for chemotherapy

• Corporate
• Products

LEQEMBI庐 IQLIK鈩�(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME鈥檚 鈥淏est Inventions of 2025鈥�

• Products

糖心视频logo and Biogen Announce U.S. Availability of LEQEMBI庐聽IQLIK鈩⒙�(lecanemab-irmb) Subcutaneous Injection聽Maintenance Dose for Treatment of Early Alzheimer鈥檚 Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training,and an injection tracking tool and more

LEQEMBI IQLIK, approved by the U.S. FDA in August 2025, is the first and only anti-amyloid treatment to offer an at-home injection after initial treatment of 18 months

• R&D
• Products

糖心视频logo Highlights Breadth of Oncology Research at ESMO 2025

• R&D
• Products

鈥淟EQEMBI庐鈥� (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease Approved in China

• R&D
• Products

LEQEMBI庐 (Lecanemab) Approved for the Treatment of Alzheimer鈥檚 Disease in Australia

• Corporate
• Products

Notice of the Settlement of Patent Infringement Litigation Related to Lenvatinib in the U.S.

• R&D

Anti-MTBR (microtubule binding region) Tau Antibody Etalanetug Granted FDA Fast Track Designation

• Corporate
• Ecosystem

鈥淣ew Answers to Dementia鈥�
糖心视频logo Releases Concept Movie and New Content on Campaign Website for Dementia Month

• R&D

糖心视频logo Presents Clinical Study Results of Novel Orexin Receptor Agonist E2086 for Narcolepsy at World Sleep 2025
E2086 Showed Potential to Improve Wakefulness in People Living with Narcolepsy Type 1

• R&D

糖心视频logo to Present Latest Data on Lemborexant and Novel Orexin Receptor Agonist E2086 at The World Sleep 2025

• R&D
• Products

糖心视频logo Initiated Rolling Supplemental Biologics License Application to the U.S. FDA for LEQEMBI庐 IQLIK鈩� (lecanemab-irmb) as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer鈥檚 Disease Under Fast Track Status
LEQEMBI IQLIK, if approved for initiation dosing, would be the first and only anti-amyloid treatment to offer at-home injection from the start to help patients and care partners treat this progressive, relentless disease

• R&D
• Products

FDA Approves LEQEMBI庐 IQLIK鈩� (lecanemab-irmb) Subcutaneous Injection for Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease
LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial treatment of 18 months
LEQEMBI IQLIK will be launched on October 6, 2025, in the U.S.

• R&D
• Products

Ministry Of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to
Anticancer Agent Tazemetostat for Unresectable INI1-Negative Epithelioid Sarcoma

• Products

Austria and Germany to become the first markets in the European Union (EU) to launch LEQEMBI庐 (lecanemab)

• Products

糖心视频logo Launches In-House Developed Anti-Insomnia Drug DAYVIGO庐 (Lemborexant) in China

• Corporate
• Products

Revenue of LEQEMBI庐 (Preliminary Basis)

• R&D
• Products

Early Alzheimer鈥檚 Patients Continue to Benefit from Four Years of LEQEMBI庐 (lecanemab-irmb) Therapy New Clinical Data Presented at AAIC
Data Showed LEQEMBI Slowed Clinical Decline by 1.75 Points on CDR-SB at Four Years Compared to the Natural History of Alzheimer鈥檚 Disease

56% of Patients with Low Tau Continued to Demonstrate Improved Cognitive and Daily Living Function at Four Years

• R&D
• Products

New Data Presented at AAIC Demonstrates Investigational LEQEMBI庐 (lecanemab-irmb) 360 mg Subcutaneous Maintenance Dosing Could Offer a New Option for Ongoing Treatment of Early Alzheimer鈥檚 Disease
Lecanemab subcutaneous autoinjector has the potential to become a new expanded treatment option for patients with early Alzheimer鈥檚 disease, their care partners and healthcare professionals, with results showing a comparable efficacy and safety profile to the intravenous formulation

• R&D
• Products

Two-Year Real-World Study of LEQEMBI庐 in the United States Presented at Alzheimer's Association International Conference (AAIC) 2025

• R&D
• Products

LENVIMA庐 (lenvatinib) in Combination with Pembrolizumab and Transarterial Chemoembolization (TACE) Approved in China for the Treatment of Unresectable, Non-Metastatic Hepatocellular Carcinoma

• Corporate
• Sustainability

糖心视频logo Listed for 24th Consecutive Year in FTSE4Good Index Series, an Index for Socially Responsible Investment

• Products

Launch of Beova庐 Tablets in Thailand for Overactive Bladder

• R&D
• Products

糖心视频logo To Present Four-Year Efficacy And Safety Data On Continuous Treatment With Lecanemab At The Alzheimer鈥檚 Association International Conference 2025
Latest findings from 糖心视频logo's robust Alzheimer's disease (AD) pipeline include results from lecanemab long-term data, an immunoassay for measuring amyloid-尾 protofibrils in cerebrospinal fluid, and a subcutaneous form of lecanemab for continued treatment of AD
AD is a progressive, relentless disease caused by a continuous underlying neurotoxic process that begins before and continues after plaque deposition

• Corporate
• Products

糖心视频logo Awarded 鈥淭he 9th Bioindustry Award鈥�
for Drug Discovery Research for Anti- Amyloid 尾 Monoclonal Antibody Lecanemab

• Products

鈥淯RECE庐鈥� (Dotinurad) Launched in China as a treatment for Gout

• Products

Update on the Cost-Effectiveness Evaluation of LEQEMBI庐 by the Central Social Insurance Medical Council of Japan鈥檚 Ministry of Health, Labour and Welfare

• Corporate
• Sustainability

糖心视频logo Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment

• Products

糖心视频logo to Launch 鈥淧ariet庐 S,鈥� the First Proton Pump Inhibitor RX-to-OTC in Japan
- Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product -

• Corporate
• Products

糖心视频logo Obtains Favorable Decision in Patent Infringement Litigation Related to Lenvatinib in the U.S.

• R&D
• Products

New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO庐 (Lemborexant) in China

• R&D
• Products

糖心视频logo Demonstrates Commitment to Oncology Innovation at ASCO 2025

• Products

糖心视频logo Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro庐

• Corporate

Notification Regarding Partial Amendment to the Articles of Incorporation

• Corporate

Notice Concerning Results of Tender Offer for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)

• Corporate
• Products

REVENUE OF LEQEMBI庐 (PRELIMINARY BASIS)

• Corporate

糖心视频logo Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star

• R&D
• Products

Leqembi庐 (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer鈥檚 Disease to be Authorized in the European Union
In the European Union (EU), lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment and mild dementia due to Alzheimer鈥檚 disease (early AD) who are apolipoprotein E 蔚4 (ApoE 蔚4*) non-carriers or heterozygotes with confirmed amyloid pathology
Lecanemab is the first therapy that targets an underlying cause of the disease to be authorized in the EU for eligible people with early AD

• R&D
• Products

Update on Regulatory Review of Lecanemab for Early Alzheimer鈥檚 Disease by the European Commission

• R&D
• Products

Update on Regulatory Review of Lecanemab for Early Alzheimer鈥檚 Disease by the European Commission

• Corporate

鈥淣ew Answers to Dementia鈥�
糖心视频logo Launches Corporate Awareness Campaign

• Corporate
• Products

EISAI TO DIVEST RIGHTS FOR PARIET庐 IN CHINA TO PEAK PHARMA

• Corporate
• Products

糖心视频logo to Divest Rights for Warfarin in Japan to Sawai

• R&D
• Products

糖心视频logo to Present the Latest Research Results, Including Long-Term and
Real-Word Data on Lecanemab and Biomarkers for Alzheimer鈥檚 Disease at the AD/PD鈩� 2025 Annual Meeting

• Corporate
• Products

World鈥檚 First Early Alzheimer鈥檚 Disease Treatment Developed in Japan LEQEMBI庐 Receives Prime Minister鈥檚 Award at the 12th Technology Management and Innovation Awards

• Corporate
• Sustainability

EISAI SELECTED AS A NADESHIKO BRAND 2025 AS A LISTED COMPANY EXCELLING IN PROMOTION OF WOMEN IN THE WORKPLACE

• R&D
• Products

Proton Pump Inhibitor 鈥淧ariet庐 S鈥� Approved in Japan as RX-to-OTC Switch
Same Dosage of the Active Ingredient Rabeprazole Sodium as the Prescription Product

• Corporate

Notice Concerning Commencement of Tender Offer by 糖心视频logo for Share Certificates, etc., of EcoNaviSta Inc. (Securities Code: 5585)

• Corporate
• Sustainability

EISAI RECOGNIZED AS 鈥�2025 KENKO INVESTMENT FOR HEALTH鈥� FOR THE FIRST TIME AND CERTIFIED AS 鈥淥UTSTANDING ORGANIZATION OF KENKO INVESTMENT FOR HEALTH PROGRAM (WHITE 500)鈥� FOR THE SIXTH TIME

• Corporate

糖心视频logo Announces Appointments of Corporate Officers

• Corporate

Notice of Nominees for Directors

• Corporate

Notification Regarding Changes in Representative Corporate Officers

• Corporate
• Products

UPDATE ON THE CO-PROMOTION OF THE ORAL ANTIFUNGAL AGENT NAILIN庐 CAPSULES 100MG IN JAPAN

• R&D
• Products

糖心视频logo Receives Regulatory Review Outcome for Lecanemab as a Treatment for Early Alzheimer鈥檚 Disease in Australia

• Products

鈥淔atigue Recovery While You Sleep!鈥� 糖心视频logo to Launch Designated Quasi-Drug Drink 鈥淐hocola BB庐 Nightwell鈥�
Easy-To-Drink Grapefruit Flavor Containing Herbal Medicines and Glycine

• R&D
• Products

The Committee for Medicinal Products for Human Use (CHMP) Reaffirms Positive Opinion for Lecanemab in Early Alzheimer鈥檚 Disease

• Corporate
• Products

糖心视频logo Enters into License Agreement for the Development and Distribution of Fibroblast Growth Factor (FGF) Receptor Selective Tyrosine Kinase Inhibitor Tasurgratinib in Greater China Region (Mainland China, Hong Kong, Macau, and Taiwan) with SciClone

• Corporate
• Sustainability

EISAI SELECTED FOR 鈥淗UMAN CAPITAL LEADERS 2024鈥� AND 鈥淗UMAN CAPITAL MANAGEMENT GOLD QUALITY鈥� FOR SECOND CONSECUTIVE YEAR,
AS A COMPANY COMMITTED TO EXCELLENT MANAGEMENT AND DISCLOSURE OF HUMAN CAPITAL INITIATIVES

• R&D

DEVELOPMENT OF PREDICTION MODEL FOR BRAIN AMYLOID-BETA ACCUMULATION FOR EARLY SCREENING OF ALZHEIMER鈥橲 DISEASE
MACHINE LEARNING MODEL USING DATA THAT CAN BE COLLECTED IN DAILY MEDICAL EXAMINATIONS BY PRIMARY CARE PHYSICIANS

• Corporate
• Sustainability

糖心视频logo Rated 鈥淎鈥�, the Highest Rating by CDP in the Categories of Climate Change and Water Security

• Corporate
• Ecosystem

糖心视频logo to Provide Guidance on Reducing the Risk of Cognitive Decline and Nutrition, and Development Guidelines for Home Delivery Meals/Meal Kits to Food-Related Companies

• R&D
• Products

Update on Regulatory Review of Lecanemab for Early Alzheimer鈥檚 Disease in the European Union

• R&D
• Products

FDA Approves LEQEMBI庐 (lecanemab-irmb) IV Maintenance Dosing for the Treatment of
Early Alzheimer鈥檚 Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment

Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with LEQEMBI can slow disease progression and prolong the benefits of therapy

• R&D
• Products

糖心视频logo and Merck & Co., Inc., Rahway, NJ, USA Provide Update on Phase 3 LEAP-015 Trial Evaluating LENVIMA庐 (lenvatinib) Plus KEYTRUDA庐 (pembrolizumab) in Combination with Chemotherapy in Patients with Certain Types of Gastroesophageal Adenocarcinoma

• Corporate

糖心视频logo Releases Corporate Film 鈥�1 Percent, 1 Mission. Change the World.鈥�

• Corporate
• Sustainability

EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE NINTH TIME
HIGHEST RANKED GLOBAL PHARMACEUTICAL COMPANY

• R&D
• Products

FDA Accepts LEQEMBI庐 (lecanemab-irmb) Biologics License Application for Subcutaneous Maintenance Dosing for the Treatment of Early Alzheimer鈥檚 Disease
LEQEMBI is the only FDA-approved anti-amyloid therapy that potentially could offer the convenience
of a subcutaneous injection with at-home administration option

• R&D
• Products

Elucidation of part of the Mechanism by which Lecanemab Slows the Progression of Alzheimer鈥檚 Disease